Adaptive Biotechnologies Corp
Decodes the adaptive immune system to develop products for diagnosing and treating disease.
ADPT | US
Overview
Corporate Details
- ISIN(s):
- US00650F1093
- LEI:
- Country:
- United States of America
- Address:
- 1165 EASTLAKE AVE E, 98109 SEATTLE
- Website:
- https://www.adaptivebiotech.com
Description
Adaptive Biotechnologies Corp. is a commercial-stage company focused on immune-driven medicine. It specializes in decoding the adaptive immune system to develop clinical products for diagnosing and treating diseases. The company operates an Immune Medicine Platform that sequences T-cell and B-cell receptors to generate immune receptor data. This data is applied across life sciences research, clinical diagnostics, and drug discovery. A key offering is clonoSEQ, a highly sensitive, next-generation sequencing (NGS) assay for assessing Minimal Residual Disease (MRD) in certain blood cancers. This product is utilized in both clinical practice and biopharmaceutical drug trials. The company aims to harness the immune system's natural capabilities as a tool to transform disease detection and treatment.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Adaptive Biotechnologies Corp filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Adaptive Biotechnologies Corp
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Adaptive Biotechnologies Corp via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
